Yike Medical Secures Millions in Angel Funding; 26-Province Urological Consumables Centralized Procurement Advances

1. The Beijing-Tianjin-Hebei branch of the National Medical Products Administration's Center for Drug and Device Evaluation has been established in Beijing.

Recently, a press conference on the comprehensive deepening of pharmaceuticals and medical device regulatory reforms to promote the high-quality development of the pharmaceutical industry in Beijing was held. The Beijing-Tianjin-Hebei branch of the National Medical Products Administration (NMPA) Center for Drug and Device Evaluation officially began operations in late September. This center will serve Beijing, Tianjin, Hebei, and Shandong, providing comprehensive technical services such as pre- and post-evaluation guidance, consultation acceptance, and evaluation communication for drug and medical device evaluations. It will also undertake relevant registration inspections and巡回inspections. The branch will promote regional collaborative regulation, with its operations integrated into the unified work systems, business processes, and evaluation standards of the NMPA’s Drug Evaluation Center, Device Evaluation Center, and Inspection Center. The establishment of the branch will advance the unification of inspection standards and mutual recognition of resources across the Beijing-Tianjin-Hebei-Shandong region. Additionally, through joint inspections led by the branch, regional inspection resources will be consolidated, reducing inspection cycles. (Qingtong Perspective)

2. The 26-province urology consumables centralized procurement advances further.

Recently, the Chongqing Municipal Medical Security Bureau issued the "Notice on Publicly Soliciting Opinions for the Draft Document of the Provincial Alliance Centralized Bulk Procurement of Ureteral Stent Medical Consumables (Draft for Comments)." This indicates that the urology surgery consumables alliance procurement, covering 26 provinces including Chongqing, Tianjin, Hebei, Shanxi, and Inner Mongolia, has officially entered the preparation stage. As a key consumable in urological surgeries, ureteral stents have long been dominated by imported brands such as Boston Scientific and Cook in the market. According to data from the National Medical Products Administration, although there are currently 114 domestically approved ureteral stents, imported brands still hold an advantageous position in the high-end product sector, particularly in long-term indwelling products like alloy stents. The launch of this centralized procurement comes as China’s medical consumables bulk procurement system enters a new phase of normalization and institutionalization. The 26-province alliance procurement led by Chongqing, together with the sixth batch of national procurement, forms a policy synergy, which may lead to a new round of market restructuring and opportunities for domestic alternatives in the urology consumables market. (21st Century Economic Report)

3. Call for Participating Units in the Group Standard of "Intelligent Medical Sensing and Detection Technology"

Recently, the Medical Device Science and Technology Innovation Professional Committee of the China Technology Market Association has organized Tianjin Medical University to lead the development of the group standard for "Intelligent Medical Sensing and Detection Technology," and is now publicly soliciting participating organizations. Intelligent medical sensing and detection technology is a core frontier technology in the field of medical devices, but there are currently issues such as inconsistent technical specifications, which have constrained its promotion and adaptation. The standard will focus on the design, performance, and testing methods of intelligent medical sensors, aiming to establish unified norms, ensure clinical safety and effectiveness, and promote high-quality industry development. Participating organizations include those involved in technology research and development, production and manufacturing, testing services, clinical applications, and education and research. Participating organizations can engage in standard drafting discussions, access technical materials, and enhance industry influence, but must assign professionals to attend meetings, cooperate with technical investigations, and adhere to the drafting schedule. (China Medical Device Procurement Public Service Platform)

4. Non-invasive Full-brain Multi-channel Oxygen Monitor Approved for Marketing

Recently, the innovative product "Non-invasive Whole-brain Multi-channel Oxygen Monitor" by Casibrain (Beijing) Technology Co., Ltd. has been officially approved for marketing. Previously, this product entered the special review process for innovative medical devices by the National Medical Products Administration (NMPA). It is a globally pioneering medical device capable of simultaneous and continuous non-invasive oxygen monitoring across multiple brain regions, including the frontal, parietal, occipital, and temporal lobes. The successful market launch of the "Non-invasive Whole-brain Multi-channel Oxygen Monitor" marks a breakthrough in the global field of non-invasive brain function monitoring — transitioning from "single-point monitoring" to a new phase of "panoramic monitoring." Additionally, the product expands the application scenarios for non-invasive brain oxygen monitors: from primarily being used during anesthesia procedures to broader fields such as neurosurgery, intensive care, and stroke prevention and treatment. In particular, it further meets the critical needs of numerous stroke centers for precise diagnosis, treatment, and prognosis rehabilitation assessment in real clinical settings. (Vcbeat)

5. "Nanchang-Made" Brain Science Medical Devices Rank Among the Most Advanced in China

Recently, the transcranial magnetic stimulator independently developed by Puzhuo Medical, a company in Nanchang Economic Development Zone, successfully made it to the list of Jiangxi Province's "First (Set) Major Technical Equipment," marking Nanchang’s entry into the forefront of China in the field of brain science medical devices. With core technologies such as multi-target loop regulation and millisecond-level pulse control, the device breaks the single-target treatment model of traditional neuromodulation equipment, offering non-invasive rehabilitation options for patients with stroke, Parkinson’s, and others. Its version 3.0 adds an optical navigation system, enabling precise regulation and significantly improving treatment outcomes. Developed in collaboration with the Institute of Automation, Chinese Academy of Sciences, the device divides the brain into 246 functional sub-regions, far surpassing international mainstream standards in accuracy. During the R&D process, the team overcame the technical bottleneck of nearly 2,000 volts of high-voltage withstand, innovatively adopting "cascade topology technology." (Sina)

6. Edan Initiates Local Manufacturing in the United States

Recently, Edan's manufacturing center located in San Diego, California, USA, has been officially put into operation, realizing localized production of products in the United States. Previously, Edan's U.S. subsidiary had been deeply cultivating the local market for 15 years, forming a market penetration and customer service network covering major regions. The newly added manufacturing center strengthens Edan's business layout in the United States and the entire North American region, further enhancing supply chain resilience and overall service capabilities. As Edan's localized manufacturing center established in the United States, it covers an area of 20,882 square feet (approximately 1,940 square meters). Relying on Edan's existing marketing network in the United States, it will extend upstream and downstream capabilities, continuously deepen global resource collaboration, further expand production capacity, improve operational efficiency, shorten service response cycles, thereby more quickly and accurately meeting the growing medical needs of the North American market. (Sina Finance)

7. What is the medical device public service platform?

The Medical Device Public Service Platform is jointly developed by the Orthomed Group in collaboration with local governments, parks, medical institutions, and research universities. It focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device technology projects. By establishing a scientific research and transfer mechanism that aligns with international standards and implementing an open and shared operational model, the platform attracts top-tier scientific researchers, doctors, and innovators from around the world. It provides comprehensive industry technical services encompassing R&D transformation, incubation, and investment, nurturing significant innovative achievements and applications in medical devices. This initiative strongly supports the development of the medical device industry and technological innovation. (Compiled by Orthomed)

8. Eke Medical Completes Millions of Yuan in Angel Round Financing

Recently, Wuxi Eke Medical Device Co., Ltd. completed an angel round of financing worth several million yuan, exclusively invested by Vertex Ventures. The funds from this round will mainly be used for core technology innovation, product development, market expansion, team expansion, and other purposes, further consolidating its leading position in the non-invasive neuromodulation sector. Eke Medical, established in June 2023, specializes in the field of non-invasive neuromodulation technology. Its self-developed Eunuo® wearable low-frequency therapy device received medical device registration approval in April 2025. In practical clinical applications, this product has shown positive therapeutic effects on essential tremor (ET) and upper limb tremors caused by some cases of Parkinson's disease (PD). (Investment界)